Cataract. Capsular glaucoma with pseudo exfoliation of lens (H40.1
Conditions
Interventions
Intervention 1: Intervention 1: Tablet Tamsulosin Hydrochloride 0.4 mg, once a day for four days, Brand name Flomax , manufacturer Farabi Pharmaceutical. Intervention 2: Intervention 2: Placebo.
Prevention
Intervention 1: Tablet Tamsulosin Hydrochloride 0.4 mg, once a day for four days, Brand name Flomax , manufacturer Farabi Pharmaceutical
Sponsors
Chancellor for research, Hamadan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
52 Years to 84 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : No contraindications for general anesthesia and general Surgery. Patients with spontaneous urine output less than 100 ml in the first eight hours after surgery, and completely distended palpable bladder Exclusion criteria: Congestive Heart Failure, Myocardial Infarction, Renal Failure, Hypotension (Systolic Blood Pressure less than 100 mmHg), hypersensitivity to the drug, IPSS score greater than 25 or less than 15 and patients with a permanently Foley catheter
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary Retention. Timepoint: Every one hour, until 8 hours from surgery, patients will be examined for urination or probable urinary retention. Method of measurement: Failure to void and patients need to urethra catheterization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Floppy Iris. Timepoint: During surgery. Method of measurement: Any iris dropping during surgery that report by surgeon and interfere with surgery. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKarampourian Arezo
Hamadan University of Medical Sciences
Outcome results
None listed